Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000736 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals
A Phase 3 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 3
- Development phase
- 3,200
- Enrollment target
NCT00000736 is a Phase 3 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 3,200 participants.
The verdict
NCT00000736, a Phase 3 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,200 participants
- Enrollment target
Study Summary
To determine if treatment with zidovudine (AZT) will delay or prevent the onset of AIDS or AIDS related complex (ARC) in individuals infected with HIV but who do not have symptoms of AIDS or ARC. Also, to compare the dose of AZT found to be useful in AIDS and severe ARC with a lower dose to see if side effects can be reduced. Results from several studies show that a high percentage of people infected with HIV will eventually develop AIDS or ARC unless an effective treatment is found. Because AZT is known to prolong survival in patients with AIDS or severe ARC and has acceptable toxicity in advanced disease, it is reasonable to try it in less advanced cases.
Interventions
- DRUG Zidovudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,200 participants |
| Est. Completion | 1995-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000736
The ClinicalTrials.gov registry entry for NCT00000736 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Zidovudine is the first listed.
NCT00000736 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000736 about?
NCT00000736 is a clinical study titled "Safety and Efficacy of Zidovudine for Asymptomatic HIV-Infected Individuals". To determine if treatment with zidovudine (AZT) will delay or prevent the onset of AIDS or AIDS related complex (ARC) in individuals infected with HIV but who do not have symptoms of AIDS or ARC. Also, to compare the dose of AZT found to be useful in AIDS and severe ARC with a lower dose to see if s...
What is the current status of trial NCT00000736?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,200 participants. Estimated completion is 1995-02.
What interventions are being tested in trial NCT00000736?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00000736?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.